Checkpoint Therapeutics Inc expected to post a loss of $1.07 a share - Earnings Preview

Checkpoint Therapeutics

13/05/2023 03:01

* Checkpoint Therapeutics Inc  CKPT.OQ   CKPT.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 15 (estimated). 
    * The Waltham Massachusetts-based  company is expected to
report 
a 67.9% decrease in revenue to $16.67 thousand from $52 thousand
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Checkpoint
Therapeutics
Inc is for a loss of $1.07 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 2.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $34​, above​ its last closing price
of $2.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -1.30       -1.31      -2.29     Missed  -75.3
 Sep. 30 2022  -1.47       -1.47      -1.20     Beat    18.2
 Jun. 30 2022  -1.78       -1.72      -1.60     Beat    7.2​
 Mar. 31 2022  -1.39       -1.42      -2.00     Missed  -40.8
 ​​Dec.        -1.50       -1.54      -3.90     Missed  -153.2
 31 2021                                                
 Sep. 30 2021  -1.34       -1.36      -1.40     Missed  -2.9​
 Jun. 30 2021  -1.01       -1.04      -1.20     Missed  -15.4
 Mar. 31 2021  -1.10       -1.05      -0.90     Beat    14.3
 This summary was machine generated May 13 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated